Neuropsychiatric aspects of coinfection with HIV and hepatitis C virus

AIDS Reader

Volumn 18, Issue 8, 2008, Pages

  Douaihy, Antoine ^a   Hilsabeck, Robin C ^b,c   Azzam, Pierre ^d   Jain, Abhishek ^d   Daley, Dennis C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Coinfection; Hepatitis c; HIV AIDS; Neuropsychiatric disorder

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

BIPOLAR DISORDER; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DYSTHYMIA; GENERALIZED ANXIETY DISORDER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; MENTAL DISEASE; MIXED INFECTION; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PANIC; PERSONALITY DISORDER; POSTTRAUMATIC STRESS DISORDER; PSYCHOLOGIC TEST; REVIEW; TEAMWORK; TREATMENT PLANNING; CENTRAL NERVOUS SYSTEM DISEASE; PSYCHOLOGICAL ASPECT;

CENTRAL NERVOUS SYSTEM DISEASES; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 51449098162     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. 1. Lauer GM, Walker BD. Hepatitis C virus infection. IV Engl J Med.2001;345:41-52.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831-837.
3. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV coinfection. AIDS. 2004;18:1-12.
4. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV international panel. AIDS. 2002;16:813-828.
5. American Academy of Neurology. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778-785.
6. Grant I, Atkinson JH. Neuropsychiatry aspects of HIV infection and AIDS. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry/Vll. Baltimore: Williams & Wilkins; 1999: 308-335.
7. Cherner M, Cysique L, Heaton RK, et al; HNRC Group. Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol. 2007; 13:23-28.
8. Heaton RK, Grant I, Butters N, et al. The HNRC 500 - neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J hit Neuropsychol Soc. 1995;1:231-251.
9. Marcotte TD, Grant I, Atkinson JH, et al. Neurobehavioral complications of HIV infection. In: Tarter RE, Butters M, Beers SR, eds. Medical Neuropsychology. 2nd ed. New York: Kluwer Academic/Plenum Publishers; 2001:285-331.
10. Hinkin CH, Castellon SA, Hardy DJ, et al. Computerized and traditional Stroop task dysfunction in HIV-1 infection. Neuropsychology. 1999;13:306-316.
11. Hinkin CH, Castellon SA, Hardy DJ. Dual task performance in HIV-1 infection. J Clin Exp Neuropsychol. 2000;22:16-24.
12. Archibald SL, Masliah E, Fennema-Notestine C, et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol. 2004;61:369-376.
13. Cloak CC, Chang L, Ernst T. Increased frontal white matter diffusion is associated with glial metabolites and psychomotor slowing in HIV. J Neuroitn- munol. 2004;157:147-152.
14. Paul RH, Yiannoutsos CT, Miller EN, et al. Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci. 2007;19:283-292.
15. Moore DJ, Masliah E, Rippeth JD, et al; HNRC Group. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS. 2006;20:879-887.
16. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(suppl 1):S19-S25.
17. Waldrop-Valverde D, Ownby RL, Wilkie FL, et al. Neurocognitive aspects of medication adherence in HIV-positive injecting drug users. AIDS Behav. 2006; 10:287-297.
18. Marcotte TD, Lazzaretto D, Scott JC, et al; HNRC Group. Visual attention deficits are associated with driving accidents in cognitively-impaired HIV-infected individuals. J Clin Exp Neuropsychol. 2006;28: 13-28.
19. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology. 2002;59:1563-1567.
20. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3-10.
21. Carey CL,Woods SP, Rippeth JD, et al; HNRC Group. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychologist. 2004;18:234-248.
22. Sacktor N, McDermott MP, Marder K, et al. HIV- associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8: 136-142.
23. Cohen RA, Boland R, Paul R, et al. Neurocognitive performance enhanced by highly active anti- retroviral therapy in HIV-infected women. AIDS. 2001;15:341-345.
24. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV- l -associated neurocognitive impairment. AIDS. 1999;13:1889-1897.
25. Avison MJ, Nath A, Greene-Avison R, et al. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. / Neurovirol. 2004;10:223-232.
26. Letendre S, Marquie-Beck J, Singh KK, et al. HNRC Group. The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol. 2004;157:193-196.
27. Singh KK, Ellis RJ, Marquie -Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment in HIV -l -infected adults. J Neuroimmunol. 2004; 157:185-192.
28. St Hillaire C, Vargas D, Pardo CA, et al. Aqua- porin 4 is increased in association with human immunodeficiency virus dementia: implications for disease pathogenesis. J Neurovirol. 2005;11:535-543.
29. Atkinson JH Jr, Grant I, Kennedy CJ, et al. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: a controlled study. Arch Gen Psychiatry. 1988;45:859-864.
30. Perkins DO, Stern RA, Golden RN, et al. Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994;151:233-236.
31. Sherbourne CD, Hays RD, Fleishman JA, et al. Impact of psychiatric conditions on health-related quality of life in person with HIV infection. Am J Psychiatry. 2000;157:248-254.
32. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728.
33. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
34. Israelski DM, Prentiss DE, Lubega S, et al. Psychiatric co-morbidity in vulnerable populations receiving primary care for HIV/AIDS. AIDS Care. 2007;19:220-225.
35. Tsao JC, Dobalian A, Moreau C, Dobalian K. Stability of anxiety and depression in a national sample of adults with human immunodeficiency virus. J New Ment Dis. 2004;192:111-118.
36. Centers of Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005. Vol 17. Rev ed. Atlanta: CDC, US Department of Health and Human Services; 2007:1-46.
37. Buchacz K, McFarland W, Kellogg TA, et al. Amphetamine use is associated with increased HIV incidence among men who have sex with men in San Francisco. AIDS. 2005;19:1423-1424.
38. Meade CS, Graff FS, Griffin ML, Weiss RD. HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse. Drug Alcohol Depend. 2008;92:296-300.
39. Castellon SA, Hinkin CH, Wood S, Yarema K. Apathy, depression, and cognitive performance in HIV-1 infection. J Neuropsychiatry Clin Neurosci. 1998;10: 320-329.
40. Beyer JL, Taylor L, Gersing KR, et al. Prevalence of HIV infection in a general psychiatric outpatient population. Psychosomatics. 2007;48(l):31-37.
41. Cole MA, Castellon SA, Perkins AC, et al. Relationship between psychiatric status and frontal-sub- cortical systems in HIV-infected individuals. J Int Neuropsychol Soc. 2007;13:549-554.
42. Kim TW, Palepu A, Cheng DM, et al. Factors associated with discontinuation of antiretroviral therapy in HIV-infected patients with alcohol problems. AIDS Care. 2007;19:1039-1047.
43. Douaihy AB, Stowell KR, Kohnen S, et al. Psychiatric aspects of comorbid HIV/AIDS and pain, Part 2. AIDS Reader. 2007;350-352,357-361.
44. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
45. Mooney S, Hassanein TI, Hilsabeck RC, et al; UCSD Hepatology Neurobehavioral Research Program. Utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in patients with end-stage liver disease awaiting liver transplant. Arch Clin Neuropsychol. 2007;22:175-186.
46. Sorrell JH, Zolnikov BJ, Sharma A, Jinnai 1. Cognitive impairment in people diagnosed with end- stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci. 2006;60:174-181.
47. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007; 102:1903-1909.
48. Wein C, Koch H, Popp B, et al. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology. 2004;39:739-745.
49. Fontana RJ, Bieliauskas LA, Back-Madruga C, et al; HALT-C Trial Group. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol. 2005;43:614-622.
50. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology. 2002;35:440-446.
51. Hilsabeck RC, Hassanein TI, Carlson MD, et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9:847-854.
52. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001; 358:38-39.
53. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with inild liver disease. Hepatology. 2002;35: 433-439.
54. Kramer L, Bauer E, Funk G, et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepmtol. 2002;37:349-354.
55. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005;41:801-808.
56. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain - evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol. 2004;41:845-851.
57. Amodio P, De Toni EN, Cavalletto L, et al. Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord. 2005;84:93-98.
58. Capuron L, Pagnoni G, Demetrashvili M, et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry. 2005;58:190-196.
59. Hilsabeck RC, Hassanein TI, Ziegler EA, et al. Effect of interferon- alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2005;11:16-22.
60. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Bert). 2000;152: 383-389.
61. Kraus MR, Schafer A, Wissmann S, et al. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther. 2005;77:90-100.
62. Lieb K, Engelbrecht MA, Gut O, et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFN-α): results from a prospective study. Eur Psychiatry. 2006;21:204-210.
63. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition - the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041-2056.
64. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol. 2006;172:38-58.
65. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157:683-694.
66. Forton DM, Allsop JM, Cox IJ, et al. A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. AIDS. 2005;19(suppl 3):S53-S63.
67. Fontana R[, Hussain KB, Schwartz SM, et al. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol. 2002;36:401-407.
68. el-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476-482.
69. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C- positive patients. Psychosomatics. 2001;42:411-415.
70. Dwight MM, Kowdley KV, Russo JE, et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res. 2000; 49:311-317.
71. Barkuizen A, Rosen HR, Wolf S, et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355-1360.
72. US Department of Veterans Affairs. Hepatitis C. http://www.hepatitis.va. gov. Accessed July 9, 2008.
73. Fontana RJ- Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis. 2000,18:107- 116.
74. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alfa: a review. Am J Psychiatry. 2000;157: 867-876.
75. Rosenberg SD, Drake RE, Brunette MF, et al. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS. 2005;19(suppl3):S26-S33.
76. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am j Psychiatry. 2000;157:683-694.
77. Gochee PA, Powell EE, Purdie DM, et al. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alfa treatment for chronic hepatitis C. Psychosomatics. 2004; 45:49-57.
78. Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19(suppl3):S64-S71.
79. Hilsabeck RC, Castellon SA, Hinkin CH. Neuropsychological aspects of coinfection with HIV and hepatitis C virus. Clin Infect Dis. 2005;41(suppl 1): S38-S44.
80. Martin EM, Novak RM, Fendrich M, et al. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc. 2004;10:298-300.
81. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr. 2004;35:131- 137.
82. Richardson JL, Nowicki M, Danley K, et al. Neuropsychological functioning in a cohort of HIV- and hepatitis C virus-infected women. AIDS. 2005;19: 1659-1667.
83. Cherner M, Letendre S, Heaton RK, et al; HIV Neurobehavioral Research Center Group. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005; 64:1343-1347.
84. Letendre SL, Cherner M, Ellis RJ, et al; HNRC Group. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS. 2005;19(suppl3):S72- S78.
85. Paul R, Letendre S, Dearborn J. Impact of hepatitis C coinfection on cognitive outcomes in HIV-infected individuals. Curr Hepatitis Rep. 2007;6:145-152.
86. Letendre S, Paulino AD, Rockenstein E, et al. HIV Neurobehavioral Research Center Group. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis. 2007;196:361-370.
87. Laskus T, Radkowski M, Adair DM, et al. Emerging evidence of hepatitis C virus neuroinvasion. AIDS. 2005:19(suppl 3):S140-S144.
88. Laskus T, Radkowski M, Jablonska J, et al. Human immunodeficiency virus facilitates infection / replication of hepatitis C virus in native human macrophages. Blood. 2004;103:3854-3859.
89. Perry W, Carlson MD, Barakat F, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. J Acquir Immune Defic Syndr. 2005;19(suppl 3):S79-S84.
90. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hep- atology. 1999;30:1054-1058.
91. Backus LI, Boothroyd D, Deyton LR. HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations. AIDS. 2005;19(suppl 3):S13-S19.
92. Ryan EL, Morgello S, Isaacs K, et al; The Manhattan HIV Brain Bank. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology. 2004;62:957-962.
93. Hilsabeck RC, Carlson MD, Ziegler EA, et al. Comparison of psychiatric symptoms in patients with hepatitis C, human immunodeficiency virus, and coinfection. J Neuropsychiatry Clin Neurosci. 2003; 15:281.
94. Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hep- atitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19(suppl 3):S64-S71.
95. Braitstein P, Montessori V, Chan K, et al. Quality of life, depression and fatigue among persons coinfected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care. 2005;17:505- 515.
96. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest. 2005;127:1205- 1211.
97. Grassi L, Satriano ], Serra A, et al. Emotional stress, psychosocial variables and coping associated with hepatitis C virus and human immunodeficiency virus infections in intravenous drug users. Psycho- ther Psychosom. 2002;71:342-349.
98. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-613.
99. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284-1292.
100. Zinkernagel C, Taffe P, Rickenbach M, et al; Swiss HIV Cohort Study. Importance of mental health assessment in HIV-infected outpatients. J Acquir Immune Defic Syndr. 2001;28:240-249.
101. Hinkin CH, Aronow HA, Hilsabeck RC, et al. Psychiatric and cognitive concomitants of HIV and HCV co-infection. National Institute on Drug Abuse (NIDA) symposium on issues in the medical management of HIV / HCV co-infection in IDUs (Washington, DC). Bethesda, MD: NIDA, 2004:8.
102. Marcellin F, Preau M, Ravaux I, et al. Self- reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and hepatitis C: implications for clinical management and future research. HIV Clin Trials. 2007;8:320-327.
103. Graham CS, Koziel MJ. First things first: balancing hepatitis C and human immunodeficiency virus. Clin Infect Dis. 2003;36:368-369.
104. Fleming CA, Tumilty S, Murray JE, Nunes D. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis. 2005;40(suppl 5):S349-S354.
105. Selwyn PA, Rivard M. Palliative care for AIDS: challenges and opportunities in the era of highly active anti- retroviral therapy. J Palliat Med. 2003:6:475- 487.
106. Samet JH, Phillips SJ, Horton NJ, et al. Detecting alcohol problems in HIV-infected patients: use of the CAGE Questionnaire. AIDS Res Hum Retroviruses. 2004;20:151-155.
107. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin liver Dis. 2004;24:305-315.
108. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology. 2002;36(5 suppl 1):S220-S225.
109. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon - induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-947.
110. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis. 2005;40(suppl 5):S355-S361.
111. Tedaldi EM, Baker RK, Moorman AC, et al; HIV Outpatient Study (HOPS) Investigators. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antirerroviral therapy. Clin Infect Dis. 2003;36:363-367.
112. Clanon KA. Strategies for managing hepatitis C virus infection in HIV-infected patients. Top HIV Med. 2003;11:50-54.
113. Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis. 2005;41(suppl 1):S83-S88.
114. Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS. 2005;19 (suppl 3):S227-S237.
115. Aoki N, Xing Z. Use of cytokines in infection. Expert Opin Emerg Drugs. 2004;9:223-236.
116. Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep. 2004;6:60-65.